Denali Therapeutics Inc. has exercised an option to acquire its partner F-star Gamma for $24m upfront, in a deal potentially worth more than $470m to the parent company F-star GMBH.
F-star CEO John Haurum told Scrip the acquisition validated the F-star’s model, through which the company has spun out several...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?